ACHL News and Press, Achilles Therapeutics plc From 04/12/22

The Center for Breakthrough Medicines (CBM) Strikes Multi-Year Deal with UK Cell Therapy Powerhouse PR Newswire Strategic Partnership to Deliver US Based Manufacturing Capacity for Novel Cell Therapy KING OF PRUSSIA, Pa. , April 12, 2022 /PRNewswire/ ...

LONDON, April 05, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced that management will be taking part in the following conferences in April. Acc...

- Webcast will feature Professor Charles Swanton, TRACERx Chief Investigator and Achilles co-founder - - Panel will discuss how TRACERx real-world data enable Achilles’ AI-powered PELEUS bioinformatics platform to identify and validate clonal neoantigens as targets for personaliz...

LONDON, March 08, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced its participation in the 32nd Annual Oppenheimer Healthcare Conference taking place vi...

PHILADELPHIA, March 01, 2022 (GLOBE NEWSWIRE) -- Netrality announced today that Achilles Therapeutics plc [NASDAQ: ACHL], a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, has leased 7,243 SF of lab space at 401 North Broad. Ac...

Achilles Therapeutics press release (NASDAQ:ACHL): Q4 GAAP EPS of -$0.45 beats by $0.31. Cash and cash equivalents were $266.3 million as of December 31, 2021, as compared to $177.8 million as of December 31, 2020. For further details see: Achilles Therapeutics GAAP EPS of -$0.45 b...

- Patient data from higher dose cNeT as monotherapy and cNeT in combination with checkpoint inhibitor expected in 2H 2022 - - Strong cash position of $266 million supports clinical development and manufacturing expansion into 2H 2024 - LONDON, March 01, 2022 (GLOBE NEWSWIRE...

LONDON, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced the appointment of Alena Gros, Ph.D. and Ben Creelan, M.D. to its Scientific Advisory B...

LONDON, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announces a business update and reflects on recent progress with its pioneering, personalized T c...

LONDON, Dec. 21, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced that Iraj Ali, Chief Executive Officer, will present at the virtual 40th Annual J.P. Mo...